GSK’s ViiV to work with Medicines Patent Pool, generic manufacturers to bolster access to long-acting HIV prevention med Apretude fkansteiner Fri, 05/27/2022 – 08:32 More: GSK's ViiV to work with Medicines Patent Pool, generic manufacturers to bolster access to long-acting
read moreFaricimab is administered as an eye injection with an interval of up to 16 weeks More: Thousands to potentially benefit from Roche treatment for sight loss Source: News
read moreInitial group of patients have received Saphnelo in a phase 3 trial evaluating lupus nephritis More: AstraZeneca kidney inflammation treatment trial reaches dosing stage Source: News
read morePfizer and Moderna rapidly falling out of favor as Americans’ favorite brands: report badams Fri, 05/27/2022 – 07:15 More: Pfizer and Moderna rapidly falling out of favor as Americans' favorite brands: report Source: fierce
read moreASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug kdunleavy Thu, 05/26/2022 – 16:13 More: ASCO: Seagen, Takeda think Adcetris can become a force as a lymphoma combo drug Source: fierce
read moreASCO: Bristol Myers delves into Opdualag’s LAG-3 melanoma win in key populations aliu Thu, 05/26/2022 – 12:18 More: ASCO: Bristol Myers delves into Opdualag's LAG-3 melanoma win in key populations Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals